- Patients with resected localized primary nonsquamous stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations had significantly better disease-free survival (DFS) than those who received placebo.
Why this matters
- Adjuvant chemotherapy is the current standard of care in patients with resected stage II-III NSCLC and select stage IB patients, but high recurrence rates suggest additional therapies are needed.
- Phase 3, double-blind, randomized ADAURA trial.
- 682 patients with surgically resected primary nonsquamous stage IB/II/IIIA NSCLC with EGFR mutations received osimertinib (n=339) or placebo (n=343).
- Funding: AstraZeneca.
- In patients with stage II-IIIA, DFS was significantly better with osimertinib (HR, 0.17; P<.0001>
- 2-year DFS: 90% in the osimertinib group vs 44% in the placebo group.
- None included.